The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities that receive the discounts from drug manufacturers.
Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback